Is Horizon Pharma PLC a Sell? The Stock Had Bearish Options Activity Today

 Is Horizon Pharma PLC a Sell? The Stock Had Bearish Options Activity Today

In today’s session Horizon Pharma PLC (HZNP) recorded an unusually high (755) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the January, 2017 put, expecting serious HZNP decrease. With 755 contracts traded and 83374 open interest for the Jan, 17 contract, it seems this is a quite bearish bet. The option with symbol: HZNP170120P00015000 closed last at: $1.1 or 15.8% up. About 577,938 shares traded hands. Horizon Pharma PLC (NASDAQ:HZNP) has risen 33.23% since April 27, 2016 and is uptrending. It has outperformed by 28.00% the S&P500.

Analysts await Horizon Pharma PLC (NASDAQ:HZNP) to report earnings on March, 6. They expect $0.52 earnings per share, 0.00% or $0.00 from last year’s $0.52 per share. HZNP’s profit will be $83.83M for 9.99 P/E if the $0.52 EPS becomes a reality. After $0.56 actual earnings per share reported by Horizon Pharma PLC for the previous quarter, Wall Street now forecasts -7.14% negative EPS growth.

Horizon Pharma PLC (NASDAQ:HZNP) Ratings Coverage

Out of 9 analysts covering Horizon Pharma (NASDAQ:HZNP), 6 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 67% are positive. $40 is the highest target while $21 is the lowest. The $28.33 average target is 36.33% above today’s ($20.78) stock price. Horizon Pharma has been the topic of 21 analyst reports since September 9, 2015 according to StockzIntelligence Inc. On Monday, November 23 the stock rating was reinitiated by Jefferies with “Buy”. The company was maintained on Tuesday, November 8 by Mizuho. As per Wednesday, January 6, the company rating was reinitiated by Citigroup. Mizuho maintained the stock with “Buy” rating in Tuesday, September 13 report. The rating was reinitiated by JMP Securities on Wednesday, September 9 with “Mkt Outperform”. The company was initiated on Thursday, December 17 by Goldman Sachs. Jefferies initiated the shares of HZNP in a report on Tuesday, January 19 with “Buy” rating. Mizuho maintained Horizon Pharma PLC (NASDAQ:HZNP) on Monday, December 14 with “Buy” rating. The company was downgraded on Friday, September 16 by Cowen & Co. The company was reinitiated on Thursday, December 3 by Morgan Stanley.

According to Zacks Investment Research, “Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company’s U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon’s global headquarters are in Dublin, Ireland.”

Insitutional Activity: The institutional sentiment increased to 1.46 in Q2 2016. Its up 0.25, from 1.21 in 2016Q1. The ratio increased, as 46 funds sold all Horizon Pharma PLC shares owned while 45 reduced positions. 38 funds bought stakes while 72 increased positions. They now own 135.34 million shares or 2.87% less from 139.33 million shares in 2016Q1.
Blackrock Institutional Na holds 0.01% or 3.67M shares in its portfolio. The New York-based Jpmorgan Chase Co has invested 0.02% in Horizon Pharma PLC (NASDAQ:HZNP). Acadian Asset Mgmt Ltd Limited Liability Company, a Massachusetts-based fund reported 624 shares. Price T Rowe Md has 492,485 shares for 0% of their US portfolio. The New York-based Fincl Bank Of Mellon has invested 0% in Horizon Pharma PLC (NASDAQ:HZNP). Fund Mgmt holds 0.01% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP) for 54,027 shares. Qcm Cayman Ltd, a Texas-based fund reported 25,502 shares. Ubs Asset Management Americas holds 719,184 shares or 0.01% of its portfolio. Royal Fincl Bank Of Canada last reported 0% of its portfolio in the stock. Vanguard Incorporated last reported 10.57M shares in the company. Ghost Tree Capital reported 250,000 shares or 1.19% of all its holdings. Zurcher Kantonalbank (Zurich Cantonalbank) has 3,922 shares for 0% of their US portfolio. Invesco Ltd last reported 0% of its portfolio in the stock. Amer Natl Registered Invest Advisor Inc last reported 0.14% of its portfolio in the stock. Moreover, Dekabank Deutsche Girozentrale has 0.01% invested in Horizon Pharma PLC (NASDAQ:HZNP) for 36,800 shares.

Insider Transactions: Since June 15, 2016, the stock had 0 insider buys, and 2 selling transactions for $500,280 net activity. Nohria Virinder sold 25,000 shares worth $442,280. The insider SHERMAN JEFFREY W sold 2,900 shares worth $58,000.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The company has a market cap of $3.35 billion. The Firm is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It currently has negative earnings. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

HZNP Company Profile

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, incorporated on December 20, 2011, is a biopharmaceutical company. The Firm is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. The Firm markets approximately nine medicines through its orphan, primary care and rheumatology business units. The Company’s segment focuses on the identification, development, acquisition and commercialization of differentiated and accessible medicines. The Company’s marketed medicines include ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate and caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% w/w, or PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Firm also developed DUEXIS and RAYOS, known as LODOTRA.

More recent Horizon Pharma PLC (NASDAQ:HZNP) news were published by: Fool.com which released: “Why Horizon Pharma PLC Jumped Higher Today” on November 07, 2016. Also Seekingalpha.com published the news titled: “Horizon Pharma Plc (HZNP) Q3 2016 Results – Earnings Call Transcript” on November 07, 2016. Globenewswire.com‘s news article titled: “Horizon Pharma plc Announces Availability of RAVICTI® (glycerol phenylbutyrate …” with publication date: November 03, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment